On-body Drug Delivery Devices Market Size, Share, and Industry Analysis, By Device Type (Injectors, Infusion Pumps, and Others), By Molecule Type (Small Molecule and Large Molecule), By Usage (Disposable and Reusable), By Application (Diabetes, Cardiovascular Diseases, Cancer, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecast till, 2024-2032

On-body drug delivery devices are tools that are intended to be worn on the body to deliver the medication to the patient. These devices comprise patches, pumps, and injectors, which are directly attached to the body of the individual or patient-worn systems. These systems can either be affixed under or over the patient’s clothes. These devices are intended to provide sustained delivery of medication. The on-body drug delivery devices, such as wearable injectors, are worn on the body to deliver a specific dose at a set time. In contrast, infusion pumps deliver a continuous flow of a therapeutic agent, such as insulin, through a catheter or infusion set.

The market is witnessing significant growth driven by the growing demand for on-body drug delivery devices globally. This higher demand is primarily attributed to the substantial number of new biologic drug and corresponding biosimilar versions of these drugs, which are utilized in the treatment of an extensive range of long-term therapies.

These therapies address chronic conditions that require subcutaneous injections, which can be self-administered. Moreover, the on-body drug delivery devices facilitate the injection of parenteral drugs outside healthcare settings, which increases their adoption driving the market growth. Moreover, the companies are highly focused on manufacturing, research and development, and supply of on-body drug delivery devices for self-administration of various medications in homecare settings.

• For instance, according to Springboard, in September 2022, BD announced that their two on-body drug delivery platform (OBDS), BD Evolve on-body Injector and BD Libertas Wearable Injector, are currently under development.

The rising prevalence of chronic diseases is another major factor driving the on-body drug delivery devices market growth. Chronic diseases such as diabetes require a drug release at a controlled and sustained rate for a prolonged period, which these devices can fulfill. As a result, the higher prevalence of diabetes increases the adoption of these devices, thereby contributing to market growth.

• According to the Centers for Disease Control and Prevention, in 2022, diabetes cases have risen to an estimated 37.3 million people or 11.3% of the U.S. population.

• Furthermore, according to NCBI, the global prevalence of type 2 diabetes is anticipated to rise to 7079 individuals per 100,000 by 2030.

Such rising prevalence is expected to surge the demand for on-body drug delivery devices during the forecast period.

The global on-body drug delivery devices market witnessed negative growth during the COVID-19 pandemic. Despite the several advancements in on-body drug delivery devices, global disruption in the supply chain and manufacturing hampered the distribution and production of these devices, which have resulted into the shortages for these devices.

The reduced hospitals visits for certain therapies requiring the use of these devices limited their adoption during the COVID-19 pandemic. Moreover, the research prioritization toward the COVID-19 have resulted into delays for launches and approvals of these devices. However, the pandemic highlighted the need for more convenient and efficient on-body drug delivery, which led to increased focus on research and development for new on-body devices, which revived the rate of market growth after the pandemic.

Key Insights

The report covers the following key insights:

• Prevalence of Key Disease, By Key Countries/Regions, 2023


• Technological Advancements in On-body Drug Delivery System


• New Product Launches, By Key Players


• Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)


• Impact of COVID-19 on the Market

Segmentation

Analysis by Device Type

Based on device type, the injectors segment is projected to hold a significant share of the global market during the forecast timeframe. The significant share is primarily attributed to the growing cases of chronic diseases coupled with increasing aging population. Moreover, benefits associated with these injectors, such as convenient and effective drug delivery and the simplification of the drug administration process, are expected to increase its adoption, driving segment growth. 

• For instance, in August 2023, according to the National Council on Aging, Inc., around 95.0% of individuals 60 years of age or older have at least one chronic condition, whereas 80% have two or more. As a result, the growing number of aged individuals holding high risk of chronic diseases surge the demand for wearable injectors

Regional Analysis

North America is projected to hold the largest share of the global on-body drug delivery devices market. The increasing adoption of these devices primarily influences this growth, as they provide a user-friendly way to administer medications for several conditions in the region. The higher prevalence of chronic diseases such as diabetes in the U.S. is also expected to increase the demand for wearable injectors in this region. In addition, the well-established healthcare infrastructure supporting research and development activities in the U.S. contributes to the advancement of on-body drug delivery systems, boosting market growth.

• For instance, in January 2024, according to the University of North Carolina, scientists created a wearable patch that uses electrically triggered microneedles for on-demand, subcutaneous drug delivery. This discovery has shown promise in the treatment of neurodegenerative disorders, increasing the demand and availability of on-body drug delivery devices.

The Asia Pacific market is anticipated to witness a substantial growth rate during the projection period. This growth can be attributed to the growing population in countries such as India and China that leads to a large patient pool, propelling the adoption of on-body drug delivery devices. Moreover, the growing awareness regarding chronic diseases and increasing preference for user-friendly treatment options is expected to drive the market growth in the region.

Key Players Covered

The report includes the profiles of key players such as Gerresheimer AG, Enable Injections, Stevanato Group, Insulet Corporation., YPSOMED, Medtronic, West Pharmaceutical Services, Inc., and E3D Elcam Drug Delivery Devices (Elcam Medical).

Key Industry Developments

• In September 2023, Enable Injections, Inc. announced that it received the U.S. FDA approval for EMPAVELI Injector (infused) for the subcutaneous delivery of pegcetacoplan. This device was commercialized in the U.S. by Apellis Pharmaceuticals, Inc. for adults with paroxysmal nocturnal hemoglobinuria (PNH).


• In March 2023, Stevanato Group entered into a collaboration with Thermo Fisher Scientific, Inc. to launch its innovative on-body delivery system platform to market.


• In September 2022, Ypsomed AG announced to scale up its manufacturing capacity for YpsoDose, an on-body drug delivery device in Switzerland, with the first clinical studies that would begin in 2023.